Cargando…
Mass Screening of SARS-CoV-2 Variants using Sanger Sequencing Strategy in Hiroshima, Japan
This study aimed to develop the feasible and effective universal screening strategy of the notable SARS-CoV-2 variants by Sanger Sequencing Strategy and then practically applied it for mass screening in Hiroshima, Japan. A total of 734 samples from COVID-19 confirmed cases in Hiroshima were screened...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844052/ https://www.ncbi.nlm.nih.gov/pubmed/35165301 http://dx.doi.org/10.1038/s41598-022-04952-2 |
_version_ | 1784651400231256064 |
---|---|
author | Ko, Ko Takahashi, Kazuaki Nagashima, Shintaro E, Bunthen Ouoba, Serge Hussain, Md Razeen Ashraf Akita, Tomoyuki Sugiyama, Aya Sakaguchi, Takemasa Tahara, Hidetoshi Ohge, Hiroki Ohdan, Hideki Kubo, Tatsuhiko Ishikawa, Nobuhisa Takafuta, Toshiro Fujii, Yoshiki Mimori, Michi Okada, Fumie Kishita, Eisaku Ariyoshi, Kunie Kuwabara, Masao Tanaka, Junko |
author_facet | Ko, Ko Takahashi, Kazuaki Nagashima, Shintaro E, Bunthen Ouoba, Serge Hussain, Md Razeen Ashraf Akita, Tomoyuki Sugiyama, Aya Sakaguchi, Takemasa Tahara, Hidetoshi Ohge, Hiroki Ohdan, Hideki Kubo, Tatsuhiko Ishikawa, Nobuhisa Takafuta, Toshiro Fujii, Yoshiki Mimori, Michi Okada, Fumie Kishita, Eisaku Ariyoshi, Kunie Kuwabara, Masao Tanaka, Junko |
author_sort | Ko, Ko |
collection | PubMed |
description | This study aimed to develop the feasible and effective universal screening strategy of the notable SARS-CoV-2 variants by Sanger Sequencing Strategy and then practically applied it for mass screening in Hiroshima, Japan. A total of 734 samples from COVID-19 confirmed cases in Hiroshima were screened for the notable SARS-CoV-2 variants (B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.1, C.37, B.1.1.529, etc.). The targeted spike region is amplified by nested RT-PCR using in-house designed primer set hCoV-Spike-A and standard amplification protocol. Additionally, randomly selected 96 samples were also amplified using primer sets hCoV-Spike-B and hCoV-Spike-C. The negative amplified samples were repeated for second attempt of amplification by volume-up protocol. Thereafter, the amplified products were assigned for Sanger sequencing using corresponding primers. The positive amplification rate of primer set hCoV-Spike-A, hCoV-Spike-B and hCoV-Spike-C were 87.3%, 83.3% and 93.8% respectively for standard protocol and increased to 99.6%, 95.8% and 96.9% after second attempt by volume-up protocol. The readiness of genome sequences was 96.9%, 100% and 100% respectively. Among 48 mutant isolates, 26 were B.1.1.7 (Alpha), 7 were E484K single mutation and the rest were other types of mutation. Moreover, 5 cluster cases with single mutation at N501S were firstly reported in Hiroshima. This study indicates the reliability and effectiveness of Sanger sequencing to screen large number of samples for the notable SARS-CoV-2 variants. Compared to the Next Generation Sequencing (NGS), our method introduces the feasible, universally applicable, and practically useful tool for identification of the emerging variants with less expensive and time consuming especially in those countries where the NGS is not practically available. Our method allows not only to identify the pre-existing variants but also to examine other rare type of mutation or newly emerged variants and is crucial for prevention and control of pandemic. |
format | Online Article Text |
id | pubmed-8844052 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-88440522022-02-16 Mass Screening of SARS-CoV-2 Variants using Sanger Sequencing Strategy in Hiroshima, Japan Ko, Ko Takahashi, Kazuaki Nagashima, Shintaro E, Bunthen Ouoba, Serge Hussain, Md Razeen Ashraf Akita, Tomoyuki Sugiyama, Aya Sakaguchi, Takemasa Tahara, Hidetoshi Ohge, Hiroki Ohdan, Hideki Kubo, Tatsuhiko Ishikawa, Nobuhisa Takafuta, Toshiro Fujii, Yoshiki Mimori, Michi Okada, Fumie Kishita, Eisaku Ariyoshi, Kunie Kuwabara, Masao Tanaka, Junko Sci Rep Article This study aimed to develop the feasible and effective universal screening strategy of the notable SARS-CoV-2 variants by Sanger Sequencing Strategy and then practically applied it for mass screening in Hiroshima, Japan. A total of 734 samples from COVID-19 confirmed cases in Hiroshima were screened for the notable SARS-CoV-2 variants (B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.1, C.37, B.1.1.529, etc.). The targeted spike region is amplified by nested RT-PCR using in-house designed primer set hCoV-Spike-A and standard amplification protocol. Additionally, randomly selected 96 samples were also amplified using primer sets hCoV-Spike-B and hCoV-Spike-C. The negative amplified samples were repeated for second attempt of amplification by volume-up protocol. Thereafter, the amplified products were assigned for Sanger sequencing using corresponding primers. The positive amplification rate of primer set hCoV-Spike-A, hCoV-Spike-B and hCoV-Spike-C were 87.3%, 83.3% and 93.8% respectively for standard protocol and increased to 99.6%, 95.8% and 96.9% after second attempt by volume-up protocol. The readiness of genome sequences was 96.9%, 100% and 100% respectively. Among 48 mutant isolates, 26 were B.1.1.7 (Alpha), 7 were E484K single mutation and the rest were other types of mutation. Moreover, 5 cluster cases with single mutation at N501S were firstly reported in Hiroshima. This study indicates the reliability and effectiveness of Sanger sequencing to screen large number of samples for the notable SARS-CoV-2 variants. Compared to the Next Generation Sequencing (NGS), our method introduces the feasible, universally applicable, and practically useful tool for identification of the emerging variants with less expensive and time consuming especially in those countries where the NGS is not practically available. Our method allows not only to identify the pre-existing variants but also to examine other rare type of mutation or newly emerged variants and is crucial for prevention and control of pandemic. Nature Publishing Group UK 2022-02-14 /pmc/articles/PMC8844052/ /pubmed/35165301 http://dx.doi.org/10.1038/s41598-022-04952-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Ko, Ko Takahashi, Kazuaki Nagashima, Shintaro E, Bunthen Ouoba, Serge Hussain, Md Razeen Ashraf Akita, Tomoyuki Sugiyama, Aya Sakaguchi, Takemasa Tahara, Hidetoshi Ohge, Hiroki Ohdan, Hideki Kubo, Tatsuhiko Ishikawa, Nobuhisa Takafuta, Toshiro Fujii, Yoshiki Mimori, Michi Okada, Fumie Kishita, Eisaku Ariyoshi, Kunie Kuwabara, Masao Tanaka, Junko Mass Screening of SARS-CoV-2 Variants using Sanger Sequencing Strategy in Hiroshima, Japan |
title | Mass Screening of SARS-CoV-2 Variants using Sanger Sequencing Strategy in Hiroshima, Japan |
title_full | Mass Screening of SARS-CoV-2 Variants using Sanger Sequencing Strategy in Hiroshima, Japan |
title_fullStr | Mass Screening of SARS-CoV-2 Variants using Sanger Sequencing Strategy in Hiroshima, Japan |
title_full_unstemmed | Mass Screening of SARS-CoV-2 Variants using Sanger Sequencing Strategy in Hiroshima, Japan |
title_short | Mass Screening of SARS-CoV-2 Variants using Sanger Sequencing Strategy in Hiroshima, Japan |
title_sort | mass screening of sars-cov-2 variants using sanger sequencing strategy in hiroshima, japan |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844052/ https://www.ncbi.nlm.nih.gov/pubmed/35165301 http://dx.doi.org/10.1038/s41598-022-04952-2 |
work_keys_str_mv | AT koko massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan AT takahashikazuaki massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan AT nagashimashintaro massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan AT ebunthen massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan AT ouobaserge massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan AT hussainmdrazeenashraf massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan AT akitatomoyuki massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan AT sugiyamaaya massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan AT sakaguchitakemasa massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan AT taharahidetoshi massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan AT ohgehiroki massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan AT ohdanhideki massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan AT kubotatsuhiko massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan AT ishikawanobuhisa massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan AT takafutatoshiro massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan AT fujiiyoshiki massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan AT mimorimichi massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan AT okadafumie massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan AT kishitaeisaku massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan AT ariyoshikunie massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan AT kuwabaramasao massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan AT tanakajunko massscreeningofsarscov2variantsusingsangersequencingstrategyinhiroshimajapan |